

## The significance of lipid profile and positive troponin in predicting cardiac event

De Silva LDR<sup>1</sup>, Kumar A<sup>2</sup>, Sathian B<sup>3</sup>

<sup>1</sup>Professor and Head of Department, <sup>2</sup>Assistant Professor, Department of Biochemistry, <sup>3</sup>Lecturer, Department of Community Medicine, Manipal College of Medical Sciences, Pokhara, Nepal.

---

### Abstract

**Background:** Diagnosis of Acute cardiac event in the early stage of its onset is important in the treatment process. The development of highly sensitive and specific immunoassays for myocardial proteins such as cardiac Troponin I (cTnI) had made it possible. However Troponin indicates cardiac events only after its onset or after cardiac tissue necrosis. Traditionally such high risk subjects were identified using lipid profiles. The identification of subjects with high risk of developing cardiac event in the future is more significant as it will provide time to prevent such incidents.

**Objectives:** In this study we proposed to study the usefulness of traditional lipid profile levels in screening subjects who had developed chest pain due to cardiac event as indicated by a positive Troponin I test.

**Materials and methods:** In this retrospective study data of the 259 patients presented to the emergency department with symptoms of cardiac ischemia who underwent both Troponin and lipid profiles tests were compared with the lipid profiles of 105 normal healthy subjects (controls).

The Troponin was detected qualitatively when a specimen contains Troponin I (cTnI) above the 99th percentile (TnI >0.5 ng/ml). The Total cholesterol (TC), High density lipoproteins cholesterol (HDL), Very low density lipoproteins (VLDL), and Triacyl glycerol levels (TG) were also analysed and low density lipoprotein level (LDL) was calculated using Friedelwald formula.

**Results:** Subjects with chest pain and positive Troponin test (with confirmed cardiac event) were found to have significantly elevated levels of TC, TG, LDL and significantly reduced HDL levels when compared to the subjects who had only chest pain (Negative Troponin) and healthy controls.

**Conclusion:** Traditional lipid profile levels still can be used in screening populations to identify the subjects with high risk of developing cardiac event which is identified by highly sensitive and specific positive Troponin test.

**Key words:** Troponin, Chest pain, Cardiac event, lipid profile

---

The diagnosis of patients with acute chest pain of possible cardiac cause (MI) is challenging and positive diagnosis has psychological, social, and legal implications<sup>1</sup>. The World Health Organisation definition, requires the presence of two of the following three features: symptoms of myocardial ischemia, elevation of cardiac marker (protein or enzyme) concentrations in the blood, and a typical electrocardiographic pattern involving the development of Q waves or persistent T wave changes<sup>2</sup>. Further the American Heart Association (AHA) case definition for acute myocardial infarction (AMI) requires an “adequate set” of biomarkers: 2 measurements of the same marker at least 6 hours apart<sup>3</sup>.

The traditional cardiac enzyme assessments for the detection of MI includes the triad of Lactate dehydrogenase (LDH), aspartate transaminase (Serum Glutamate Oxaloacetate Transaminase, SGOT), and

CK-MB which is of heart origin. However the use of biochemical ‘gold-standard’ CK-MB levels has limited prognostic power<sup>1</sup>. Hence, many patients occupy CCU beds unnecessarily, and others are discharged only to return with recurrent coronary events<sup>1</sup>.

Assessment of proteins with smaller molecular mass such as Myoglobin, Heart fatty acid binding protein (which is more cardio specific) has been developed. These appear more rapidly in the blood following the onset of necrosis and may have a specific role in the early detection of MI. However, neither of these proteins are considered as cardiac markers in clinical practice<sup>2</sup>.

---

### Correspondence

Dr. LDR Desilva  
Professor and Head of Department, Biochemistry  
Manipal College of Medical Sciences, Pokhara, Nepal  
E-mail: diliprathnekumara@yahoo.com

Identification of subjects with small areas of myocardial necrosis has become possible due to the development of specific and highly sensitive immunoassays for myocardial proteins, such as cardiac Troponins T and/or I which are components of the thin filaments of the sarcomere<sup>2</sup>. Studies have shown that the magnitude of Troponin elevations has correlated consistently with the risk of death and the composite risk of death or non-fatal MI, irrespective of whether the patients had ST elevation or non-ST elevation acute coronary syndromes<sup>2</sup>. Troponin I testing had better sensitivity, specificity and prognostic value than Troponin T testing. A positive Troponin I result was a strong predictor of cardiac events (death from cardiac causes or MI) in the next 30 days. The predictive value of a negative Troponin I result was also high, with a total 30-day event rate of 0.3%, regardless of the admission ECG<sup>1</sup>.

The new diagnostic criteria include a characteristic rise and fall in blood concentrations of cardiac Troponins and/or creatine kinase (CK)-MB in the context of spontaneous ischemic symptoms or coronary intervention<sup>2</sup>. Cardiac Troponin I and T are highly sensitive and highly specific and may be elevated when CK-MB concentrations are not even mildly elevated. In addition, they may predict recurrent cardiac events in patients with acute coronary syndromes. However, use of Troponin testing has been limited by availability of laboratory-based diagnostic techniques and by relatively long processing times<sup>1</sup>.

Even minor elevations of Troponin concentrations in the blood are indicative of myocyte necrosis and not due to leakage of proteins through the myocyte cell membrane. The current immunoassays for Troponins T and I reliably detect cardiac (as distinct from skeletal muscle) forms of these proteins<sup>2</sup>. Furthermore, Troponins have greater sensitivity and specificity for the diagnosis of MI in acute myocardial ischemia.

However it is important to note that, some patients who were diagnosed of MI did not have elevated Troponins or CK values<sup>2</sup>. Some patients had died even much before the cardiac markers reach the threshold for detection<sup>2</sup>.

Further Troponin concentrations are found to be elevated in tachycardia, percutaneous coronary intervention, pulmonary emboli with right ventricular infarction, cardiac surgery, myocarditis, and renal failure, in which the cause of myocyte necrosis is not known<sup>2</sup>.

In this study we proposed to evaluate the association between lipid profile levels of the subjects with chest pain with positive or negative Troponin test.

### Materials and methods

In this retrospective study, the data of the registry maintained in the department of biochemistry of the

Manipal Teaching Hospital, Pokhara, Nepal were analyzed. The WHO case definition<sup>2</sup> was used to retrospectively assign a diagnosis in 259 patients presenting to the emergency department with symptoms of cardiac ischemia. The inclusion criteria was the subjects (n = 259) who were admitted to the Intensive care unit of the hospital complaining severe chest pain and who were requested by the medical staff to get both Troponin and lipid profiles done.

In addition to that, reports of 105 healthy subjects who had got their lipid profiles checked using the Medicare facility were assessed as controls.

The Troponin was detected qualitatively when a specimen contains Troponin I (cTnI) above the 99th percentile (TnI >0.5 ng/ml) method<sup>4</sup>. The Total cholesterol (TC), High density lipoproteins cholesterol (HDL), Very low density lipoproteins (VLDL), and Triacyl glycerol levels (TG) were analysed, using the kits provided by Human diagnostics and the low density lipoprotein level (LDL) was calculated using Friedewald formula<sup>5</sup>.

All the estimations were done using HUMAN 300 semi-auto analyser and data was analysed using Epi Info windows version. Significance of the difference of parameters among different groups was analyzed using Z - test.

The reports of the subjects with any of the missing data were excluded. The selection of the reports was done without prior knowledge of both the subjects and the staff of the intensive care unit. That is, the study by design to be double blind type. The ethical clearance was granted by the ethical committee of the Manipal College of Medical Sciences, Pokhara.

### Results

Of the 259 subjects with the chest pain and tested for the presence of Troponin in the serum qualitatively, only 38 (14.7 %) subjects were detected positive. The larger proportion of the subjects (85.3 %) with severe chest pain was found to be Troponin negative.

Initially, the differences in various lipid parameters among the subjects with chest pain and with or without a Troponin were compared (Table 1). In addition to that these two groups were compared for the same parameters with those levels of normal healthy subjects (controls).

No significant difference was observed for age among the two groups of subjects (table 1) However except for VLDL all other parameters of the lipid profiles were significantly different in two groups. Among the subjects

with chest pain Total cholesterol, triacylglycerides , low density lipoproteins levels were higher in the subjects with Troponin positive than the subjects with a negative Troponin Further HDL levels in the subjects with Troponin

The data of the table two (Table 2) shows the comparison of biochemical data of the subjects with chest pain and with or without a positive test for Troponin against the healthy controls.

Of the subjects with chest pain, a significantly ( $p < 0.001$ ) higher levels of TC, LDL and TG ( $p < 0.05$ ), have been observed in subjects with positive Troponin test, when compared to the healthy subjects( Table 2) and the subjects with a negative Troponin test (Table 1).

Further HDL level of the subjects with chest pain and

positive Troponin was significantly lower than the HDL levels of controls (Table 2) and that of the subjects with a negative Troponin test (Table 1).

The effect of sex on having only chest pain (when Troponin is negative) was evaluated and data are given in the table 3. In the subjects with chest pain which is not due to cardiac event as indicated by negative Troponin test a significantly greater levels were observed for TG and for VLDL in males than in females. However all these parameters were within the normal levels. All other parameters including TC, LDL and HDL levels were the same for both sexes.]

The effect of sex of the subjects in having chest pain with a positive Troponin ie chest pain due to cardiac event, was not evaluated as the numbers are not sufficient.

**Table 1:** Comparison of lipid parameters of the subjects with chest pain and with or without a positive Troponin test

Variable	SUBJECTS WITH CHEST PAIN ( N=259)		Significance P value
	Troponin –ve ( n=221)	Troponin +ve ( n = 38)	
Age (Yrs)	58.06 ±13.55	56.21 ± 9.94	P = 0.209
Total cholesterol(TC)mg/dl	176 ± 46.17	221 ± 35.80	P = 0.001
Triglycerides(TG) mg/dl	148.20 ± 54.79	163.74 ± 48.22	P = 0.050
Low density lipoprotein (LDL) mg/dl	102.49 ± 44.29	152.26 ± 39.41	P = 0.001
High density lipoprotein ( HDL ) mg/dl	41.09 ± 5.68	36.82 ± 5.29	P = 0.001
Very low density lipoprotein (VLDL) mg/dl	29.51 ± 10.74	31.47 ± 10.09	P = 0.147

All values are Mean ± SD

Values in the parenthesis indicate the number of subjects.

**Table 2:** The comparison of lipid profiles of the subjects with chest pain and with and without positive Troponin against healthy controls

VARIABLE	CONTROL (105)	CHEST PAIN ( 259)		P* Value
		TROPONIN	Mean ± SD	
Age yrs	55.84 ±12.61	P (38)	56.21 ± 9.94	0.436
		N ( 221)	58.9 ± 13.55	0.078
Total cholesterol mg/dl	182.24 ±52.59	P (38)	221.05 ± 5.79	0.001
		N( 221)	175.9±46.17	0.134
Triglycerides mg/dl	158.08±58.89	P (38)	163.74±48.22	0.298
		N( 221)	148.20±54.79	0.069
LDL mg/dl	105.31±48.26	P (38)	152.26±39.41	0.001
		N( 221)	102.50±44.29	0.301
HDL mg/dl	41.56±17.09	P (38)	36.82±5.29	0.047
		N ( 221)	41.091±5.683	0.356
VLDL mg/dl	31.39±12.09	P ( 38)	31.47±10.09	0.488
		N( 221)	29.51±10.75	0.076

All values are Mean ± SD

Controls = Healthy subjects

Values in the parenthesis indicated the number of subjects.

P = Subjects with chest pain and Troponin positive, N = Subjects with chest pain and Troponin negative, P\* = Significance between control and P and N groups separately

**Table 3:** The effect of sex on the variables in subjects only with chest pain (when Troponin is negative )

Variables	Males ( 145 )	Females (76 )	Significance
Age yrs	58.16 ± 13.67	57.88 ± 13.39	NS
TC mg/dl	173.13 ± 42.71	181.2 ± 52.0	NS
TG mg/dl	152.59 ± 60.05	139.8 ± 42.13	0.05
LDL mg/dl	103.58 ± 40.06	100.4 ± 47.00	NS
VLDL mg/dl	30.47 ± 11.77	27.67 ± 8.19	0.03
HDL mg/dl	41.16 ± 6.10	40.96 ± 4.83	NS

### Discussion

In a previous study of subjects with chest pain it was reported that Troponin was positive in 160 subjects (31.9%) and negative in 323 (64.3%) subjects<sup>3</sup>. They also reported higher incidence of Acute Myocardial Infarction, Acute heart failure, and death due to cardiac event in the subjects with chest pain and positive Troponin confirming that it is a powerful, independent and valuable tool for risk stratification in patients with acute chest pain. Our data indicated that, of the subjects with chest pain (259) only 38 subjects (14.7%) were detected positive and a larger proportion of subjects (85.3%) were detected negative for Troponin. Accordingly, those thirty eight subjects with chest pain are at high risk of developing cardiac event though the incidence of cardiac event is lower (14.7%).

It is well known that increased levels of low density lipoproteins (LDL), Triacylglycerides (TG) and total cholesterol (TC) and decreased levels of high density lipoproteins (HDL) are also indicative of increased incidence of cardiac events and are considered as risk factors<sup>6</sup>. Therefore in this retrospective study the relationship between levels of lipid profile parameters and the results of Troponin test in predicting cardiac events was evaluated.

The mean TC level of the subjects with positive Troponin (221 ± 35.8 (38)) was well above the recommended desirable level (< 200 mg /dl)<sup>6</sup> thus indicating those subjects are susceptible to develop cardiac event. The level of total cholesterol of the subjects with negative Troponin test but with chest pain (176 ± 46.17 (221)) was significantly lower than that of the subjects with positive Troponin above confirming the importance of maintaining total cholesterol levels below the recommended level<sup>6</sup>.

Similarly the mean TG level of the subjects with positive Troponin (163.74 ± 48.22 (38)) was well above the both the recommended desirable level<sup>6</sup> (< 150 mg /dl) and the level of TG of the subjects with negative Troponin test but with chest pain (148.20 ± 54.79 (221)). Further the TG level of the subjects with only chest pain was slightly lower than the recommended safe level.

Increased level of LDL is highly atherogenic as it could get oxidised and initiates the atheroma formation. Thus it is believed that increased level of LDL than the recommended level is a high risk factor in the development of cardiac event. The mean LDL level of the subjects with positive Troponin (152.26 ± 39.41 (38)) was well above the recommended desirable level (< 130 mg /dl)<sup>6</sup>.

Further the mean LDL level of the subjects with negative Troponin test but with chest pain (102.49 ± 44.29 (221)) was well below the recommended level and confirmed the importance of maintaining lower levels of LDL in preventing future cardiac event.

Thus our data indicated that the subjects who developed chest pain due to cardiac event as confirmed by positive Troponin test had significantly greater levels of TC, TG, LDL when compared to those levels in subjects without cardiac event as indicated by negative Troponin test.

On the other hand lower HDL level (< 40 mg/dl) is also regarded as a cardiac risk factor<sup>6</sup> and the mean HDL level of the subjects with positive Troponin (36.82 ± 5.29 (38)) was lower than the recommended safe level. This also indicate that the development of cardiac event was associated with reduced levels of HDL than the recommended level.

Further the subjects with negative Troponin test (no cardiac event) had a mean HDL level above the cut off value suggestive of safe levels and that value was (41.09 ± 5.68 (221)) significantly (p< 0.001) greater than the mean HDL levels of the subjects who had a cardiac event.

These lipid parameters were also compared with the values of aged matched hundred and five (105) healthy subjects without any known disease condition. All the values of lipid parameters are within the safe levels for healthy subjects indicating they were having a minimum possibility of developing any cardiac event. Only the mean TG level was slightly higher (158.08 ± 58.89(105)) than the risk level of 150 mg / dl.

The total cholesterol level and LDL levels of the subjects with positive Troponin was significantly ( $p < 0.001$ ) greater than the healthy subjects and no significant difference was observed for TC between healthy subjects and subjects with a negative Troponin test but with chest pain. However no significant differences were observed for TG and VLDL between these groups..

Significantly lower ( $P < 0.047$ ) mean HDL level was observed in the subjects with positive Troponin when compared to healthy subjects and the subjects only with chest pain but with negative Troponin test.

These data indicated that the chest pain due to cardiac event as determined by positive Troponin test is closely associated with elevated levels of TC, LDL, TG and also with significantly reduced HDL. However the comparison of lipid parameters of males and females in the sub group of negative Troponin tests revealed (Table 3) that there were no major significant difference of those parameters due to differences in sex.

### Conclusion

Therefore our data clearly shows that patients who developed chest pain due to cardiac event as confirmed by positive Troponin test had lipid parameters in the risk levels as suggested by ATP III<sup>6</sup>. Therefore the subjects who had lipid profile levels within risk level were at a greater risk of developing chest pain due to cardiac event. Thus it is advisable to screen and identify subjects with risk levels of lipid profile parameters and advise them to control their lipid profiles to maintain within the levels as recommended<sup>6</sup>.

Lack of previously published research papers on the relationship between lipid profiles and Troponin test for comparison and the fewer number of subjects in our study are the two major limitations in our study. Thus a larger study on this topic should be carried out

in the future to extrapolate our observation to the total population.

### Acknowledgement

We acknowledged the ethical clearance committee and the CEO and Dean of Manipal college of Medical Sciences for granting us the approval to carry out this study.

### References

1. Alp NJ, Bell JA, Shahi M. A rapid Troponin-I-based protocol for assessing acute chest pain. *Q J Med.* 2001;94:687-94.
2. John KF, Harvey DW. Clinical implications of the new definition of myocardial infarction. *Heart.* 2004;90(1): 99–106.
3. Macrae AR, Kavsak PA, Lustig V, Bhargava R, Vandersluis R, Palomaki GE, et al. Assessing the requirement for the 6 hour interval between specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. *Clin Chem.* 2006;52(5):812-8.
4. Alpert JS. Immunochromatographic Rapid Test for the Detection of Human Cardiac Troponin I in whole blood, serum, plasma. *J. Am Coll Cardiol.* 2000;36:959-69.
5. Fridewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultra centrifuge. *Clin Chem.* 1972;18:499-502.
6. Guthrie R. Meeting lipid- lowering Guideline with Statin Treatment (Part II): Rosucastatin and Atorvastatin. *Medscape Today*; [updated 2004]. Available form: <http://www.medscape.com/viewarticle1468097>